DENTAL DIGEST The British Columbia Dental Association (BCDA) appointed Quinn Mathiesen Newcomb as its CEO in September 2023. Mathiesen Newcomb has a background in leading government and stakeholder relations as well as strategy management functions. He most recently served as a senior executive at Genome BC. “Quinn’s track record of building strong relationships with diverse stakeholders, delivering successful initiatives that serve and advocate for an organization’s mandate, strategy management, and culture will enable him to effectively lead BCDA staff and support our members,” said Dr. David Lim, BCDA president, in a statement. “His commitment to service, respect, integrity, creativity, and collaboration aligns with our shared values, and he is dedicated to leading us through a new era for the profession.” Mathiesen Newcomb takes over the CEO role previously held by Jocelyn Johnston, who is retiring as CEO but will assist in the transition by remaining involved and supporting BCDA in the coming months. In early September, Jean-Yves Duclos, the Minister of Public Services and Procurement, and Mark Holland, the Minister of Health, announced that an Early Work Agreement had been awarded to Sun Life Assurance Company of Canada (Sun Life) for the Canadian Dental Care Plan (CDCP), while details of the main contract were still being finalized. As part of the announcement, the federal government indicated that up to $15 million would be provided to Sun Life to launch pre-contractual work to ensure the timely launch and successful operation of the CDCP. This includes initiating activities in such areas as recruitment, information technology and business planning. The main contract is expected to be awarded later in 2023, pending further approval. More details on the CDCP, which is expected to begin rolling out by the end of 2023, will be announced by Health Canada later this year. Quinn Mathiesen Newcomb Appointed New BCDA CEO Sun Life Awarded Contract for CDCP Groundwork ADA Clinical Practice Guidelines for the Pharmacologic Management of Acute Dental Pain in Children A panel convened by the American Dental Association (ADA) Science and Research Institute conducted a systematic review and meta-analyses to produce evidence-based recommendations for the pharmacologic management of acute dental pain after 1 or more simple and surgical tooth extractions. The guidelines also cover the temporary management of toothache (i.e., when definitive dental treatment is not immediately available) associated with pulp and furcation or periapical diseases in children under age12. The ADA Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania panel generated 7 recommendations and 5 good practice statements across conditions. Inits report, thegroupconcludedthat therewasasmallbeneficial net balance favouring the use of nonsteroidal anti-inflammatory See: bit.ly/48dSJUz Quinn MathiesenNewcomb drugs (NSAIDs) alone or in combination with acetaminophen compared with not providing analgesic therapy. They found no available evidence regarding the effect of corticosteroids on acute pain after surgical tooth extractions in children. In its conclusions, the panel stated that nonopioid medications, specifically NSAIDs like ibuprofen and naproxen alone or in combination with acetaminophen, were recommended for managing acute dental pain after 1 or more (simple and surgical) tooth extractions and the temporary management of toothache in children. Available at: jada.ada.org/article/S0002-8177(23)00390-2/fulltext 16 | 2023 | Issue 5
RkJQdWJsaXNoZXIy OTE5MTI=